[1] Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480-487.[2] Borgna-Pignatti C. The life of patients with thalassemia major. Haematologica. 2010;95(3):345-348.[3] Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051-2052.[4] Seyedifar M, Dorkoosh FA, Hamidieh AA, et al. Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran. Int J Hematol Oncol Stem Cell Res. 2016;10(4):224-231. [5] Esmaeilzadeh F, Azarkeivan A, Emamgholipour S, et al. Economic Burden of Thalassemia Major in Iran, 2015. J Res Health Sci. 2016;16(3):111-115.[6] Weidlich D, Kefalas P, Guest JF. Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom. Transfusion. 2016;56(5):1038-1045.[7] Lee TA, von Riedemann S, Tricta F. Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature. Expert Rev Pharmacoecon Outcomes Res. 2014;14(5):651-660.[8] Adly AA, Ebeid FS. Cultural preferences and limited public resources influence the spectrum of thalassemia in Egypt. J Pediatr Hematol Oncol. 2015;37(4):281-284.[9] Marwaha N. Whole blood and component use in resource poor settings. Biologicals. 2010;38(1):68-71.[10] Au WY, Li CF, Fang JP, et al. Assessment of iron overload in very young children with limited thalassemia care resources in South China. Hemoglobin. 2014;38(2):119-126. [11] Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-1995.[12] Brissot P, Ropert M, Le Lan C, et al. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta. 2012;1820(3):403-410.[13] Piga A, Longo F, Duca L, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol. 2009;84(1):29-33.[14] Cappellini MD, Motta I. New therapeutic targets in transfusion-dependent and -independent thalassemia. Hematology Am Soc Hematol Educ Program. 2017;2017(1): 278-283.[15] Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis. 2006;6(4):226-233.[16] Nienhuis AW, Persons DA. Development of gene therapy for thalassemia. Cold Spring Harb Perspect Med. 2012;2(11): a011833.[17] Bazarbachi A, Labopin M, Ghavamzadeh A, et al. Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers. Bone Marrow Transplant. 2013;48(8):1065-1069.[18] Lucarelli G, Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev. 2008;22(2):53-63.[19] Mathews V, Srivastava A, Chandy M. Allogeneic stem cell transplantation for thalassemia major. Hematol Oncol Clin North Am. 2014;28(6):1187-1200.[20] 徐宏贵,方建培.造血干细胞移植治疗β地中海贫血[J].中国实用儿科杂志,2014,29(11):818-822.[21] Li C, Wu X, Feng X, et al. A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood. 2012;120(19):3875-3881.[22] Isgrò A, Gaziev J, Sodani P, et al. Progress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia. Ann N Y Acad Sci. 2010;1202:149-154.[23] Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417-421.[24] Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood. 1996;87(5):2082-2088.[25] Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood. 2011;117(5):1745-1750.[26] Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104(4):1201-1203.[27] Gaziev J, Nguyen L, Puozzo C, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood. 2010;115(22):4597-4604.[28] Li C, Wu X, Feng X, et al. A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood. 2012;120(19):3875-3881.[29] Mathews V, George B, Viswabandya A, et al. Improved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PLoS One. 2013;8(4): e61637.[30] Hussein AA, Al-Zaben A, Ghatasheh L, et al. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major. Pediatr Blood Cancer. 2013;60(8):1345-1349.[31] Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5):811-820.[32] Ramprakash S, Agarwal RK, Dhanya R, et al. Rejection of paternal vs maternal fully matched bone marrow grafts in children with thalassemia. Bone Marrow Transplant. 2017; 52(11):1585-1586.[33] Hamidieh AA, Dehaghi MO, Paragomi P, et al. Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search. Bone Marrow Transplant. 2015;50(4):545-552.[34] Agarwal RK, Kumari A, Sedai A, et al. The Case for High Resolution Extended 6-Loci HLA Typing for Identifying Related Donors in the Indian Subcontinent. Biol Blood Marrow Transplant. 2017;23(9):1592-1596.[35] Lee JW, Kim SK, Jang PS, et al. Impact of CD34+ cell dose in children who receive unrelated PBSCT with in vivo T-cell depletion for hematologic malignancies. Bone Marrow Transplant. 2015;50(1):68-73.[36] Li C, Wu X, Feng X, et al. A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood. 2012;120(19):3875-3881.[37] Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174-1178.[38] Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013;122(6):1072-1078.[39] Jaing TH, Hung IJ, Yang CP, et al. Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. Bone Marrow Transplant. 2012; 47(1):33-39.[40] Shahrokhi S, Menaa F, Alimoghaddam K, et al. Insights and hopes in umbilical cord blood stem cell transplantations. J Biomed Biotechnol. 2012;2012:572821.[41] Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood. 2003;101(6):2137-2143.[42] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.[43] Liu Y, Yang Y, Kang X, et al. One-Step Biallelic and Scarless Correction of a β-Thalassemia Mutation in Patient-Specific iPSCs without Drug Selection. Mol Ther Nucleic Acids. 2017;6: 57-67.[44] Xu P, Tong Y, Liu XZ, et al. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs. Sci Rep. 2015;5:12065.[45] 李玲丽,张风波,李崎,等.基因修复β-地中海贫血患者诱导多能干细胞可否成为治疗的希望[J].中国组织工程研究,2017,21(9): 1463-1469.[46] Ye L, Chang JC, Lin C, et al. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci U S A. 2009;106(24):9826-9830.[47] Neumann J. Nursing challenges caring for bone marrow transplantation patients with graft versus host disease. Hematol Oncol Stem Cell Ther. 2017;10(4):192-194.[48] Andreani M, Nesci S, Lucarelli G, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 2000; 25(4):401-404.[49] Srivastava A, Shaji RV. Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy. Haematologica. 2017;102(2):214-223.[50] Andreani M, Gianolini ME, Testi M, et al. Mixed chimerism evolution is associated with T regulatory type 1 (Tr1) cells in a β-thalassemic patient after haploidentical haematopoietic stem cell transplantation. Chimerism. 2014;5(3-4):75-79.[51] Kropshofer G, Sopper S, Steurer M, et al. Successful management of mixed chimerism after bone marrow transplant in beta-thalassemia major. Am J Hematol. 2016; 91(9):E357-358. |